# Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

> **NCT03641794** · PHASE1 · UNKNOWN · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 56 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** DN1406131
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03641794
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-07
- **Primary completion:** 2019-05-13
- **Final completion:** 2019-07-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2019-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03641794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03641794, "Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03641794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*